phosphoribosyl-AMP | 1109-75-7

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: phosphoribosyl-AMP
• 英文别名: [(2R,3S,4R,5R)-5-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]-6-iminopurin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
• CAS: 1109-75-7
• 化学式: C₁₅H₂₃N₅O₁₄P₂
• 分子量: 559.32
• InChiKey: RTQMRTSPTLIIHM-KEOHHSTQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.7
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  290
• 氢给体数：
  9
• 氢受体数：
  17

反应信息

• 作为产物：
  描述：

  β-烟酰胺腺嘌呤二核苷酸 在 sodium phosphate buffer 、 potassium tert-butylate 、 水 作用下， 以 二甲基亚砜 为溶剂， 反应 5.5h， 生成 phosphoribosyl-AMP
  参考文献：
  名称：

  Cyclic ADP-Ribose: Synthesis and Structural Assignment

  摘要：

  Cyclic ADP-ribose (cADPR) is a naturally occurring cyclic nucleotide and a potent mediator of calcium mobilization in many mammalian tissues. Previous studies have shown that cADPR is synthesized from beta-NAD(+) via the scission of the nicotinamide-ribose linkage and cyclization by forming a new bond between the ribose and the nitrogen of the adenine ring. However, the position and stereochemistry of this newly formed linkage were not unequivocally determined. In this study we have established that cADPR has the anomeric carbon of the ribose attached onto the N-1-nitrogen of the adenine nucleus via a beta-N-glycosyl linkage. The structural assignment was made by correlating cADPR to N-1-(5'-phosphoribosyl)AMP, a known intermediate of histidine biosynthesis. This was achieved by cleaving the pyrophosphate bond of cADPR under conditions (DMSO/tert-butoxide) not perturbing the integrity of the C-N glycosyl bond. Furthermore, cADPR was successfully synthesized by cyclization of N-1-(5'-phosphoribosyl)ATP catalyzed by NAD(+) pyrophosphorylase in an organic solvent-aqueous medium.

  DOI：

  10.1021/ja00096a002

文献信息

• Probe compound for detecting and isolating enzymes and means and methods using the same
  申请人：Helmholtz-Zentrum für Infektionsforschung GmbH

  公开号：EP2230312A1

  公开（公告）日：2010-09-22

  The present invention relates to a probe compound that can comprise any substrate or metabolite of an enzymatic reaction in addition to an indicator component, such as, for example, a fluorescence dye, or the like. Moreover, the present invention relates to means for detecting enzymes in form of an array, which comprises any number of probe compounds of the invention which each comprise a different metabolite of interconnected metabolites representing the central pathways in all forms of life. Moreover, the present invention relates to a method for detecting enzymes involving the application of cell extracts or the like to the array of the invention which leads to reproducible enzymatic reactions with the substrates. These specific enzymatic reactions trigger the indicator (e.g. a fluorescence signal) and bind the enzymes to the respective cognate substrates. Moreover, the invention relates to means for isolating enzymes in form of nanoparticles coated with the probe compound of the invention. The immobilisation of the cognate substrates or metabolites on the surface of nanoparticles by means of the probe compounds allows capturing and isolating the respective enzyme, e.g. for subsequent sequencing.

  本发明涉及一种探针化合物，它可以包括酶反应的任何底物或代谢物，此外还包括指示成分，例如荧光染料或类似物。此外，本发明还涉及以阵列形式检测酶的方法，该阵列由任意数量的本发明探针化合物组成，每种探针化合物由代表所有生命形式中中心途径的相互关联的代谢物中的不同代谢物组成。此外，本发明还涉及一种检测酶的方法，该方法涉及将细胞提取物或类似物应用于本发明的阵列，从而导致与底物发生可重复的酶反应。这些特定的酶反应会触发指示剂（如荧光信号），并将酶与各自的同源底物结合。此外，本发明还涉及以涂覆有本发明探针化合物的纳米颗粒形式分离酶的方法。通过探针化合物将同源底物或代谢物固定在纳米颗粒表面，可以捕获和分离相应的酶，例如用于后续测序。
• METHOD FOR SCREENING ESSENTIAL METABOLITES IN GROWTH OF MICROORGANISMS
  申请人：Korea Advanced Institute of Science and Technology

  公开号：EP2097743A1

  公开（公告）日：2009-09-09
• US7869957B2
  申请人：——

  公开号：US7869957B2

  公开（公告）日：2011-01-11
• US8494779B2
  申请人：——

  公开号：US8494779B2

  公开（公告）日：2013-07-23
• [EN] METHOD FOR SCREENING ESSENTIAL METABOLITES IN GROWTH OF MICROORGANISMS<br/>[FR] PROCÉDÉ DE CRIBLAGE DE MÉTABOLITES ESSENTIELS DANS LA CROISSANCE DE MICRO-ORGANISMES
  申请人：KOREA ADVANCED INST SCI & TECH

  公开号：WO2008078911A1

  公开（公告）日：2008-07-03

  [EN] The present invention disclosed is a method for screening metabolites essential for the growth of microorganism using metabolic flux analysis. More specifically, the present invention relates to the method for screening metabolites essential for the growth of microorganism, by selecting a target microorganism, constructing a metabolic network model of the selected microorganism, inactivating the consumption reaction of each of metabolites in the constructed metabolic network model, analyzing the metabolic flux of the metabolites to select metabolites essential for the growth of the microorganism, and confirming the selected metabolites using the utilization of each of the metabolites, defined as flux sum (F ). According to the present invention, metabolites essential for the growth of microorganism, and genes involved in the essential metabolites, can be screened in a convenient manner, and drug-target genes against pathogenic microorganisms can be predicted by deleting genes associated with the metabolites screened according to the method.
  [FR] La présente invention concerne un procédé de criblage de métabolites essentiels à la croissance de micro-organisme au moyen d'une analyse de flux métabolique. Plus spécifiquement, cette invention concerne un procédé de criblage de métabolites essentiels à la croissance de micro-organisme par sélection d'un micro-organisme cible, élaboration d'un modèle de réseau métabolique du micro-organisme sélectionné, inactivation de la réaction de consommation de chacun des métabolites dans ledit modèle élaboré, analyse du flux métabolique des métabolites pour sélectionner les métabolites essentiels à la croissance du micro-organisme, et confirmation des métabolites sélectionnés via l'utilisation de chacun des métabolites, définis par la somme de flux (F). Selon la présente invention, des métabolites essentiels à la croissance de micro-organisme et des gènes impliqués dans ces métabolites essentiels peuvent être criblés d'une manière adéquate, et des gènes cibles de médicament destinés à lutter contre des micro-organismes pathogènes peuvent être prévus par suppression de gènes associés aux métabolites criblés selon le procédé.